AstraZeneca's coronavirus vaccine will be administered as a nasal spray as part of a new trial. It's thought that nasal sprays may better target immune cells in the lungs, throat and nose, making them even more effective at defending against Covid. Oxford is looking for 30 adults to get the vaccine squirted up their noses. Volunteers will be tracked for four months to see make sure it's safe as part of the initial trial. If successful, the phase one study will move on and tens or potentially hundreds more adults will be recruited to see if it can ward off the virus as well as a jab. The university's study, involving adults over 40, is part of its partnership with AstraZeneca. Other scientists in the UK began testing a different nasal spray vaccine, known as COVI-VAC, on volunteers at the start of the year. The spray, contains a genetically modified form of Covid and is being tested on 48 adults in London. COVI-VAC is a type of live attenuated vaccine, meaning trialists will get a genetically-modified version of Covid that is weaker than the real thing but still infectious. Meanwhile, Russia's Gamaleya Research Institute of Epidemiology and Microbiology is also trialing a nasal spray to deliver the country’s Sputnik V vaccine. The institute expects to complete clinical trials of the spray by the end of the year. Scientists at the University of Birmingham are also working on a nasal Covid treatment. Source: https://www.dailymail.co.uk/news/article-9402817/Oxford-University-trial-giving-AstraZeneca-Covid-vaccine-nasal-spray.html?